Achilleas Livieratos | Infectious Diseases Vaccines | Best Researcher Award

Dr. Achilleas Livieratos | Infectious Diseases Vaccines | Best Researcher Award

Medical Researcher | Stanford University | Greece

Dr. Achilleas Livieratos, PhD, MRSB, is a distinguished biomedical researcher whose work bridges immunology, infectious diseases, circadian biology, and artificial intelligence applications in health sciences. His research integrates advanced computational methods, including machine learning and multi-agent transformer frameworks, to enhance evidence generation, vaccine immunology, and drug safety analytics. He has published extensively in leading journals such as Vaccines, Pathogens, Viruses, eClinicalMedicine, and Value in Health, contributing to global understanding of immune response dynamics, precision medicine, and outcomes research. Notably, his development of MetaMind, an AI-driven framework for automated network meta-analyses, and his studies on circadian influences on influenza vaccine immunity have been recognized as groundbreaking contributions. His investigations into immune durability across respiratory viruses, including RSV, SARS-CoV-2, and influenza, as well as his exploration of alternative therapies for long COVID, have significantly advanced clinical and translational knowledge. As a lead collaborator with Stanford University and the University of California, San Francisco, Dr. Livieratos has directed international research initiatives on infectious disease modeling, biomarker discovery, and the application of AI in health outcomes research. His earlier work at the University of Oxford produced landmark discoveries in neurogenetics and circadian disruption, underpinning his multidisciplinary expertise. Through leadership in European Pharma and AI consortia, he continues to drive innovation in predictive health analytics and precision therapeutics, demonstrating an exceptional fusion of biomedical insight, computational innovation, and translational research impact.

Profiles : Google Scholar | Scopus

Featured Publication

Oliver, P. L., Sobczyk, M. V., Maywood, E. S., Edwards, B., Lee, S., Livieratos, A., et al. (2012). Disrupted circadian rhythms in a mouse model of schizophrenia. Current Biology, 22(4), 314–319.

Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B., et al. (2014). Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiology of Disease, 62, 193–207.

Wobst, H. J., Denk, F., Oliver, P. L., Livieratos, A., Taylor, T. N., Knudsen, M. H., et al. (2017). Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy. Scientific Reports, 7(1), 43198.

Livieratos, A., Gogos, C., & Akinosoglou, K. (2024). Impact of prior COVID-19 immunization and/or prior infection on immune responses and clinical outcomes. Viruses, 16(5), 685.

Livieratos, A., Gogos, C., & Akinosoglou, K. (2024). Beyond antivirals: Alternative therapies for long COVID. Viruses, 16(11), 1795.

Prof. Lang Bu | Immunity | Best Researcher Award

Prof. Lang Bu | Immunity | Best Researcher Award

Sun Yat-sen University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Prof. Lang Bu’s academic journey began with a focus on innate immunity, virus infections, and liver cancer, laying the foundation for groundbreaking research in signal transduction and tumor microenvironment. His passion for molecular biology and protein modifications has driven his career in precision medicine. His early education in these areas led him to specialize in innovative therapeutic strategies for combating cancer and viral diseases.

💼PROFESSIONAL ENDEAVORS

Prof. Bu currently serves as an Associate Researcher at the Institute of Precision Medicine in Sun Yat-sen University, where he contributes to cutting-edge research on innate immunity and viral infection. His professional experience spans consultancy projects and leadership in high-impact research. His work extends to industry collaborations, underscoring his connection between academic research and practical applications.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNITY

Prof. Bu’s research has significantly contributed to the understanding of tumor immunology, particularly focusing on innate immunity, viral infections, and liver cancer. He utilizes advanced techniques to explore signal transduction pathways and immune response mechanisms. His work in post-translational modifications and DNA sequencing has paved the way for personalized treatments, offering insights into innovative therapeutic approaches for cancer and infectious diseases.

🌍IMPACT AND INFLUENCE

Prof. Bu’s research has influenced the fields of viral immunity, tumor biology, and cancer immunotherapy. With significant contributions to global health through published works in SCI and Scopus journals, his influence extends into clinical and global health solutions. Prof. Bu’s findings aim to address critical health issues, particularly in liver cancer and virus-related diseases, ensuring impactful global influence.

📚ACADEMIC CITES

Prof. Bu has a citation index of PMID: 39255795, with 18 published journals in SCI and Scopus-indexed journals. His work has established him as a respected researcher in the areas of innate immunity and virus infection, positioning him as a key figure in advancing the scientific community’s understanding of these critical areas.

🏆RESEARCH GRANTS AND FUNDING

Prof. Bu has successfully secured research funding to support his work in tumor microenvironment and genomic technologies. His ability to attract substantial research grants has enabled further exploration into personalized cancer therapies and advanced immunotherapies, advancing the application of precision medicine.

🛡️LEGACY AND FUTURE CONTRIBUTIONS

Prof. Bu’s legacy is grounded in advancing immune-based therapies and enhancing our understanding of tumor immunity. His ongoing research into innate immunity and viral infection mechanisms is expected to contribute to groundbreaking therapeutic strategies for cancer and infectious diseases.

📑NOTABLE PUBLICATIONS

“Targeting APT2 improves MAVS palmitoylation and antiviral innate immunity”

Authors: Bu, L., Wang, H., Zhang, S., Cheng, C., Guo, J.
Publication Year: 2024
Journal: Molecular Cell
Citations: 2

“High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT”

Authors: Bu, L., Zhang, Z., Chen, J., Kuang, M., Guo, J.
Publication Year: 2024
Journal: Gut
Citations: 19

“Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis”

Authors: Gao, B., Wu, X., Bu, L., Xie, W., Guo, J.
Publication Year: 2024
Journal: Science Advances
Citations: 3

“AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy”

Authors: Zhang, X., Jiang, Q., Su, Y., Xie, W., Guo, J.
Publication Year: 2023
Journal: British Journal of Cancer
Citations: 9

“AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis”

Authors: Sun, Z., Jiang, Q., Gao, B., Li, J., Guo, J.
Publication Year: 2023
Journal: Cancer Research
Citations: 11